Clinical Trial Update: A Study to Evaluate the Demographics and Treatment Patterns of Myelofibrosis Patients Treated With Ruxolitinib in Turkey

View source ↗

Summary

A completed Turkish study analyzes demographics and treatment patterns of myelofibrosis patients treated with ruxolitinib.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis

Drugs mentioned

• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Myelofibrosis | Status: COMPLETED